Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 175

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 5
Chunk 175
---
 are
reasonably likely to have a material effect on our net loss, liquidity or capital resources, or that would cause financial information
to not necessarily be indicative of future operating results or financial condition. However, to the extent possible, certain trends,
uncertainties, demands, commitments and events are described herein.

C. Research and development, patents and licenses,
etc.

For a description of our research and development
programs and the amounts that we have incurred over the last two years pursuant to those programs, please see “ Item 5. Operating
and Financial Review and Prospects - A. Operating Results - Research and Development Expenses” and “ Item 5. Operating
and Financial Review and Prospects - A. Operating Results - Comparison of the year ended October 31, 2024 to the year ended
October 31, 2023 - Research and Development Expenses.”

D. Trend Information

Other
than as disclosed in “Item 5. Operating and Financial Review and Prospectus - Components of Operating Results”
and elsewhere in this Annual Report, we are not aware of any trends, uncertainties, demands, commitments or events for the period from
November 1, 2023 to October 31, 2024 that are reasonably likely to have a material effect on our total revenues, income, profitability,
liquidity or capital resources, or that caused the disclosed financial information to be not necessarily indicative of future operating
results or financial condition.